SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Make a comment > Terms and Conditions

  1. When posting or reading you agree:
    1. To accept full responsibility for the views you contribute.
    2. To use this function only for lawful purposes.
    3. Not to post defamatory, abusive, offensive, racist, sexist, threatening, vulgar, obscene, hateful or otherwise inappropriate comments, or to post comments which will constitute a criminal offence or give rise to civil liability.
    4. Not to post or make available any material which is protected by copyright, trade mark or other proprietary right without the express permission of the owner of the copyright, trade mark or any other proprietary right.
    5. Not to post any content that is advertising related.
    6. To evaluate for yourself the accuracy of any opinion, advice or other content.
    7. To supply your name and e mail address.
  2. Complaints
    1. You wish to complain about any content please use the "Report Abuse" feature and include details of your complaint, what action you would like us to take and how we can contact you.
  3. Monitoring
    1. Contributions to Make A Comment will be moderated before being published. If our attention is drawn to allegedly inappropriate content we reserve the right remove the material or the comment.
    2. Comments displaying advertising material will not be published.
    3. We reserve the right not to publish comments. Correspondence with contributors over comments which have been declined for publication will not be entertained.
  4. General
    1. We reserve the right to reveal your identity and contact details to third parties if we believe that you may have breached any of our terms and conditions.
    2. By posting material on Make a Comment, you grant all other users the right to obtain access to this material.
    3. You acknowledge that the author of each contribution is responsible for his or her comments.
    4. We are not responsible for the accuracy, veracity or reliability of any opinion, advice or statement made on Make A Comment unless it is edited by us. If un-modified by us, contributions shall not be considered to be reviewed, edited or approved by William Reed Business Media.
    5. Readers are asked to keep their comments concise and relevant to the topic in question.

Spotlight

Hikma buys Boehringer Ingeleheim CMO Ben Venue Labs

Ben Venue assets will bolster sterile injectables network, says Hikma

Hikma has bought defunct manufacturer Ben Venue and says it could reactivate the site in the long-term,...

Is your drug name ok? Run a role-play, says FDA

Is your drug name ok? Run a role-play, says FDA

Industry insiders have criticised new draft US Food and Drug Administration (FDA) guidance on choosing proprietary drug...

Generics: change in pill shape makes patients 66% more likely to quit

Generics: change in pill shape makes patients 66% more likely to quit

Switching patients to generic pills of a different shape and colour increases the chances they will end...

Eli Lilly swaps dry powder for insulin in Indianapolis restructure

Lilly swaps dry powders for insulin at Indiana site in post-patent shake-up

Patent expiration and a large molecule pipeline has prompted Eli Lilly to repurpose a solid oral dose...

Sterile injectables M&A could indicate return to in-house, says F&S
UPDATE

Sterile injectables M&A could indicate return to in-house production

Drugmakers are bringing sterile injectables capacity back in-house according to a Frost & Sullivan analyst, who says...

Glenmark to build first US manufacturing plant

Glenmark to build first US manufacturing plant

India-based Glenmark Pharmaceuticals has announced plans to set up a new oral solid dosage manufacturing facility in...

Key Industry Events

 

Access all events listing

Our events, Events from partners...